MCM
ABBV icon

Marathon Capital Management’s AbbVie ABBV Stock Holding History

Marathon Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Sell
6,832
-125
-2% -$27.7K 0.33% 58
2025
Q4 		$1.59M Buy
6,957
+678
+11% +$154K 0.34% 57
2025
Q3 		$1.45M Hold
6,279
– – 0.33% 59
2025
Q2 		$1.17M Sell
6,279
-53
-0.8% -$9.85K 0.3% 62
2025
Q1 		$1.33M Sell
6,332
-25
-0.4% -$4.86K 0.35% 58
2024
Q4 		$1.13M Sell
6,357
-50
-0.8% -$9.19K 0.28% 60
2024
Q3 		$1.27M Sell
6,407
-15
-0.2% -$2.8K 0.31% 59
2024
Q2 		$1.1M Buy
6,422
+205
+3% +$34K 0.28% 65
2024
Q1 		$1.13M Sell
6,217
-50
-0.8% -$8.62K 0.27% 65
2023
Q4 		$971K Sell
6,267
-225
-3% -$32.8K 0.24% 76
2023
Q3 		$968K Sell
6,492
-150
-2% -$22K 0.24% 72
2023
Q2 		$895K Sell
6,642
-68
-1% -$9.97K 0.22% 74
2023
Q1 		$1.07M Sell
6,710
-22,555
-77% -$3.45M 0.26% 70
2022
Q4 		$4.73M Sell
29,265
-154
-0.5% -$23.6K 1.3% 19
2022
Q3 		$3.95M Sell
29,419
-177
-0.6% -$25.4K 1.13% 19
2022
Q2 		$4.53M Buy
29,596
+121
+0.4% +$18.5K 1.46% 12
2022
Q1 		$4.78M Sell
29,475
-242
-0.8% -$35.2K 1.37% 15
2021
Q4 		$4.02M Sell
29,717
-198
-0.7% -$23.4K 0.94% 21
2021
Q3 		$3.23M Buy
29,915
+50
+0.2% +$5.71K 0.73% 28
2021
Q2 		$3.36M Sell
29,865
-125
-0.4% -$14.1K 0.78% 26
2021
Q1 		$3.25M Buy
29,990
+1,330
+5% +$142K 0.86% 24
2020
Q4 		$3.07M Buy
28,660
+1,325
+5% +$127K 0.9% 21
2020
Q3 		$2.39M Sell
27,335
-976
-3% -$91.9K 0.87% 23
2020
Q2 		$2.78M Buy
28,311
+1,175
+4% +$103K 1.07% 19
2020
Q1 		$2.07M Buy
27,136
+1,035
+4% +$88.2K 0.95% 17
2019
Q4 		$2.31M Buy
26,101
+17,185
+193% +$1.43M 0.79% 22
2019
Q3 		$675K Buy
+8,916
New +$611K 0.27% 51
2019
Q2 		– Sell
-2,516
Closed -$202K – 113
2019
Q1 		$202K Hold
2,516
– – 0.09% 94
2018
Q4 		$231K Buy
2,516
+155
+7% +$13.6K 0.11% 84
2018
Q3 		$223K Hold
2,361
– – 0.09% 96
2018
Q2 		$218K Hold
2,361
– – 0.08% 88
2018
Q1 		$223K Sell
2,361
-150
-6% -$16.5K 0.09% 91
2017
Q4 		$242K Hold
2,511
– – 0.09% 77
2017
Q3 		$223K Sell
2,511
-250
-9% -$19K 0.09% 69
2017
Q2 		$200K Buy
+2,761
New +$186K 0.09% 74
2015
Q4 		– Sell
-4,661
Closed -$254K – 89
2015
Q3 		$254K Hold
4,661
– – 0.13% 63
2015
Q2 		$313K Hold
4,661
– – 0.14% 55
2015
Q1 		$273K Buy
4,661
+400
+9% +$24.2K 0.12% 64
2014
Q4 		$279K Hold
4,261
– – 0.26% 56
2014
Q3 		$246K Sell
4,261
-50
-1% -$2.78K 0.22% 64
2014
Q2 		$243K Sell
4,311
-100
-2% -$5.25K 0.2% 67
2014
Q1 		$227K Hold
4,411
– – 0.17% 70
2013
Q4 		$233K Sell
4,411
-200
-4% -$9.83K 0.17% 66
2013
Q3 		$206K Buy
+4,611
New +$204K 0.18% 64

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marathon Capital Management's ABBV Position: Q1 2026 in Review

Marathon Capital Management reduced its AbbVie (ABBV) stake by 1.8% in Q1 2026, selling an estimated $27.7K and leaving 6,832 shares worth $1.49M. The position accounts for 0.33% of the portfolio, ranked #58.

Marathon Capital Management first reported a position in ABBV in Q3 2013 and has held it in 44 quarters since. The position peaked at $4.78M in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Marathon Capital Management held 6,832 shares of AbbVie worth $1.49M as of Q1 2026.
  • Marathon Capital Management sold 125 AbbVie shares in Q1 2026, an estimated $27.7K.
  • AbbVie made up 0.33% of Marathon Capital Management's portfolio in Q1 2026, its #58 holding.
  • Marathon Capital Management first reported a position in AbbVie in Q3 2013 and has held it in 44 quarters since.
  • Marathon Capital Management's AbbVie position peaked at $4.78M in Q1 2022.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Marathon Capital Management's 13F filing for Q1 2026, filed 14 May 2026.